Our results are in accordance with economic evaluations in other countries comparing first-line osimertinib, gefitinib, or afatinib in advanced EGFR-mutated NSCLC, which may help clinicians and administrators determine the preferred economic treatment strategy (Aziz et al., 2020; Khoo and Gao, 2021). Here, EGFR is linked to non-small cell lung carcinoma.